Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Following Liver Transplantation for High-Risk HCC
NCT04168944Phase 3Unknown
- Sponsor
- Renji Hospital
- Start
- Nov 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04168944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168944.